Diagnostic Indicators of Superimposed Preeclampsia in Women With CKD by Wiles, Kate et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ekir.2019.03.012
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Wiles, K., Bramham, K., Seed, P. T., Kurlak, L. O., Mistry, H. D., Nelson-piercy, C., ... Chappell, L. C. (2019).
Diagnostic Indicators of Superimposed Preeclampsia in Women With CKD. Kidney International Reports, 1-4.
https://doi.org/10.1016/j.ekir.2019.03.012
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 23. May. 2019
CLINICAL RESEARCHCorre
dren’s
don, S
Recei
March
KidneyDiagnostic Indicators of Superimposed
Preeclampsia in Women With CKD
Kate Wiles1, Kate Bramham2, Paul T. Seed3, Lesia O. Kurlak4, Hiten D. Mistry4,
Catherine Nelson-Piercy5, Liz Lightstone6 and Lucy C. Chappell3
1Department of Women and Children’s Health, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London,
London, UK; 2Department of Renal Medicine, King’s College Hospital NHS Foundation Trust, London, UK; 3Department of
Women and Children’s Health, King’s College London, London, UK; 4Division of Child Health, Obstetrics & Gynaecology,
School of Medicine, University of Nottingham, Nottingham, UK; 5Guy’s and St Thomas’ NHS Foundation Trust and Imperial
College Healthcare NHS Trust, London, UK; and 6Imperial College London and Imperial College Healthcare NHS Trust, London,
UKIntroduction: Diagnosis of superimposed preeclampsia in women with chronic kidney disease (CKD) is
complicated by the presence of hypertension and proteinuria due to renal disease. The aims of this study
were to determine mechanistic links between superimposed preeclampsia and renin-angiotensin system
activation, endothelial pathology, complement dysfunction, and tubular injury, and to explore the role of
diagnostic indicators of superimposed preeclampsia.
Methods: Plasma and urinary biomarkers derived from the renin-angiotensin system (active renin,
angiotensinogen), endothelial glycocalyx (hyaluronan, intercellular adhesion molecule, vascular cell
adhesion molecule [VCAM], P-selectin, E-selectin), complement activation (C3a, C5a, complement factor H,
C5b-9), and tubular injury (kidney injury molecule-1, urinary lipocalin-2) were quantiﬁed in 60 pregnant
women with CKD including 15 women at the time of superimposed preeclampsia diagnosis and 45 women
who did not develop superimposed preeclampsia, 18 women with preeclampsia, and 20 normal preg-
nancies. Correlation with placental growth factor was assessed.
Results: Plasma concentrations of hyaluronan (67.5 ng/ml vs. 27.5 ng/ml, P ¼ 0.0017, receiver operating
characteristic area 0.80) and VCAM (1132 ng/ml vs. 659 ng/ml, P < 0.0001, receiver operating characteristic
area 0.86) distinguished women with CKD and superimposed preeclampsia from those without super-
imposed preeclampsia, and correlated with placental growth factor concentration. The diagnostic
discrimination of markers of the renin-angiotensin system was reduced by adjustment for chronic hy-
pertension, antihypertensive drug use, and black ethnicity. Other markers offered limited or no diagnostic
discrimination for superimposed preeclampsia.
Conclusion: This study suggests that endothelial dysfunction contributes to the pathophysiology of
superimposed preeclampsia and a diagnostic role for plasma hyaluronan and VCAM is hypothesized.
Kidney Int Rep (2019) -, -–-; https://doi.org/10.1016/j.ekir.2019.03.012
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ª 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I t is estimated that up to 3% of women who becomepregnant have underlying CKD,1 which is associated
with adverse pregnancy outcomes including pre-
eclampsia, fetal growth restriction, preterm delivery,
and decline in maternal renal function.
A diagnosis of preeclampsia is made on the basis of de
novo hypertension developing after 20 weeks’ gestation
in conjunction with either new proteinuria or evidencespondence: Kate Wiles, Department of Women and Chil-
Health, St. Thomas’ Hospital, Lambeth Palace Road, Lon-
E1 7EH. E-mail: kate.wiles@kcl.ac.uk
ved 25 October 2018; revised 11 February 2019; accepted 11
2019; published online 26 March 2019
International Reports (2019) -, -–-of maternal organ or uteroplacental dysfunction.2 In
women with CKD, the diagnosis of superimposed pre-
eclampsia is complicated by coexisting chronic hyper-
tension and/or proteinuria, which are estimated to be
present in one-half and one-third of pregnancies,
respectively,3,4 thereby rendering standard diagnostic
criteria redundant. In the absence of formal diagnostic
criteria for superimposed preeclampsia, meta-analysis
estimates a 10-fold increased overall risk for the
development of superimposed preeclampsia in women
with CKD compared with women without CKD,5 with
preeclampsia affecting 20% to 87% of pregnancies in
women with CKD, depending on prepregnancy disease
stage and the diagnostic criteria used.3,61
CLINICAL RESEARCH K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKDPreeclampsia remains a key determinant of adverse
pregnancy outcome, contributing to preterm delivery
and maternal and neonatal morbidity in both the gen-
eral obstetric population7 and in women with CKD.4,8
The disease trajectory and associated morbidity of
preeclampsia require distinction from gestational
change in CKD, yet unless systemic or fetal complica-
tions of preeclampsia arise, discrimination of super-
imposed preeclampsia from CKD remains challenging.
Although used,3,4,8 the diagnostic value of relative
changes in both blood pressure and proteinuria in
preeclampsia remain unclear.2 Diagnostic utility has
however been demonstrated in the use of angiogenic
(placenta growth factor [PlGF]) and antiangiogenic
(soluble fms-like tyrosine kinase-1) biomarkers in pre-
eclampsia in the general population,9–11 with emerging
data on their use as a diagnostic adjunct in pregnant
women with CKD.4,12,13
The pathophysiological processes by which CKD
confers an increased risk of superimposed pre-
eclampsia remain poorly understood. Putative mecha-
nisms, which offer a mechanistic link between renal
disease and preeclampsia, include endothelial
dysfunction,14–16 renin-angiotensin system (RAS)
activation,17 complement dysregulation,18–20 and kid-
ney injury.21,22
This aim of this study was to explore mechanistic
links and investigate potential diagnostic indicators
in superimposed preeclampsia linked to pathophysi-
ology, including markers of the RAS (active renin,
angiotensinogen), endothelial glycocalyx dysfunction
(hyaluronan, intercellular adhesion molecule, VCAM,
P-selectin, E-selectin), complement activation (C3a,
C5a, complement factor H, C5b-9), and kidney injury
(kidney injury molecule-1, urinary lipocalin-2).
Given the inherent complexity in diagnosing super-
imposed preeclampsia in women with CKD and the
emerging diagnostic role of PlGF, a, correlation be-
tween the novel markers and PlGF concentration was
examined.METHODS
Pregnant women with and without CKD, and
nonpregnant women with CKD were recruited at 3
London centers (Guy’s and St. Thomas’ NHS Founda-
tion Trust, Imperial College Healthcare NHS Trust,
King’s College Hospital NHS Trust) between 2009 and
2015. Approval was provided by the Research Ethics
Service and the Health Research Authority (11/LO/1776
and 15/WA/0009). Inclusion criteria were women of
reproductive age with a known diagnosis of CKD based
on Kidney Disease: Improving Global Outcomes2criteria,23,24 in addition to pregnant women with a
presumed diagnosis of CKD based on either a raised
creatinine (>85 mmol/l) in the absence of risk factors
for acute kidney injury, or persistent proteinuria
(urinary protein:creatinine ratio >30 mg/mmol) before
20 weeks’ gestation.
Pregnant women were enrolled prospectively.
Plasma (EDTA) and urine samples were collected at
routine outpatient attendance. Samples were stored on
ice before being centrifuged at 1500g for 10 minutes at
4 oC. The separated supernatant was aliquoted and
stored at 80 oC.
Outcomes were based on predetermined criteria. In
the absence of prepregnancy hypertension and pro-
teinuria, standard diagnostic criteria were used for the
diagnosis of superimposed preeclampsia.2 For women
with preexisting hypertension and proteinuria, in
whom isolated rises in blood pressure and proteinuria
are insufﬁcient for a diagnosis of superimposed pre-
eclampsia,2 predeﬁned diagnostic criteria for the pur-
poses of this study included either the development of
severe hypertension (>160/110 mm Hg) or an incre-
ment in antihypertensive treatment to maintain blood
pressure <160/110 mm Hg, a doubling of proteinuria
above the pathological threshold for pregnancy (300
mg/24 hours or urinary protein:creatinine ratio >30
mg/mmol), or clinical features of preeclampsia
including liver involvement (alanine transaminase >71
U/l, right upper quadrant or epigastric pain), platelet
count <100,000/ml, pulmonary edema, new-onset ce-
rebral or visual disturbance, and fetal growth restric-
tion.4 In addition, all complex cases were reviewed and
a diagnosis conﬁrmed by 2 senior clinical staff with
expertise in renal disease in pregnancy (KB, LCC, LL)
assessing independently, and without access to study
results.
Obstetric outcomes included mode of delivery,
gestational age, preterm delivery deﬁned as <37
and <34 weeks’ gestation, neonatal unit admission,
birthweight, and birthweight centile assessed as a
customized birth weight percentile calculated using the
Gestation Related Optimal Weight method by freely
available software (www.pi.nhs.uk/download/graw/
GRAWCentv1.xls25). Small for gestational age was
reported as <10th and <3rd centile.
A nested case-control group was retrospectively
selected based on time of disease (preeclampsia/super-
imposed preeclampsia). This included all women with
CKD who had biological samples taken at the time of a
diagnosis of superimposed preeclampsia. These women
were matched for CKD stage and week of gestation with
pregnant women with CKD who did not develop
superimposed preeclampsia, and for week of gestationKidney International Reports (2019) -, -–-
K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKD CLINICAL RESEARCHwith pregnant women without CKD who did, and did
not, develop preeclampsia. Additional analysis of
discriminatory plasma biomarkers was carried out in
nonpregnant women of reproductive age with
advanced CKD to assess the effect of reduced renal
clearance on biomarker concentration.
Given that chronic hypertension is known to be an
independent modiﬁer of RAS,26–28 the case-control
group was extended to facilitate additional RAS anal-
ysis in women with, and without, chronic hyperten-
sion. This extended group included biological samples
at gestations that were unmatched between study
subgroups.
Biomarker Analysis
Plasma and urine samples were tested with masking of
clinical outcomes. The selection of speciﬁc analytes was
based on hypothesized mechanistic links between renal
disease and preeclampsia, feasibility in the context of
sampling methodology and long-term storage of bio-
logical samples at 80oC, and the authors’ experience
of biomarker research in pregnancy.4,9,29 Hyaluronan,
active renin, angiotensinogen, and complement com-
ponents (C3a, C5a, C5b-9, complement factor H) were
quantiﬁed using speciﬁc enzyme-linked immunosor-
bent assay kits according to manufacturers’ protocols.
Although the MIcroVue SC5b-9 enzyme-linked immu-
nosorbent assay is not validated for urine, quantiﬁca-
tion of urinary C5b-9 has been achieved.30,31
Predilution of urine was not required to achieve
quantiﬁcation of urinary C5b-9 within the detectable
range, and plate shaking at 80 revolutions per minute
was added to the manufacturer’s protocol during both
conjugate and substrate incubations to achieve satis-
factory assay performance in urine, as previously
described.32 Extraction of C5a in urine was insufﬁ-
ciently sensitive and analysis was not possible. Plasma
concentrations of intracellular adhesion molecule,Table 1. Biomarker assay details
Analyte Assay kit
Active renin IBL GMBH RE53321
Angiotensinogen IBL GMBH REJP27412
Hyaluronan R&D DHYALO
C3a Hycult Biotech HK354
C5a Hycult Biotech HK349
Complement factor H Microvue SC5–9 Plus EIA
C5b-9 Hycult Biotech HK342
Intercellular adhesion molecule R&D Human Adhesion Molecules LKT007
Vascular cell adhesion molcule
P-selectin
E-selectin
Kidney Injury Molecule -1 R&D Kidney Biomarker Premixed Kit FCSTM16
Lipocalin 2 (NGAL)
Urine creatinine Roche Diagnostics enzymatic creatinine method
Kidney International Reports (2019) -, -–-VCAM, P-selectin, E-selectin, and Kidney Injury
Molecule-1, and urinary concentrations of lipocalin-2
(NGAL) were quantiﬁed simultaneously using a Lumi-
nex (Austin, TX) Performance Assay multiplex kit ac-
cording to the manufacturer’s protocol and read by a
Luminex FlexMap3D analyzer system. Urine creatinine
was quantiﬁed to report urinary biomarker concen-
trations as a normalized ratio to urinary creatinine
concentration. Plasma PlGF was quantiﬁed using the
Triage PlGF Test by Alere (Waltham, MA).4,33 Manu-
facturers’ details and measures of precision are given in
Table 1.
Statistical Analysis
Categorical data were examined by the use of Fisher
exact test. For continuous data, a Mann-Whitney test
was used. As the biomarkers had log-normal distribu-
tions, t-tests of log-transformed data were used to
generate geometric mean ratios of biomarker concen-
tration, including interval regression as appropriate for
concentrations censored at the upper or lower limit of
detection. Although the study subgroups were
matched for prepregnancy CKD stage and sample
gestation, interval regression was also used to examine
for any signiﬁcant effect due to these variables.34
Nonparametric receiver operating characteristic curve
analyses examined the capacity of each biomarker to
discriminate preeclampsia from normal pregnancy,
both in women with and without CKD. Optimal cut-
points were determined for each discriminatory
biomarker through the examination of the Youden In-
dex35 in women with and without CKD. To correct for
gestational variation, plasma PlGF concentration bet-
ween 20 and 37 weeks was transformed into a PlGF
centile calculated using data from 1366 samples from
247 women without preeclampsia.33 Correlation be-
tween the biomarkers of interest and PlGF centile was
measured using nonparametric Spearman correlation.Detectable range Intra-assay CV (%) Inter-assay CV (%)
0.81–128 pg/ml 4.0 11.6
0.31–20 ng/ml Plasma 4.2
Urine 4.8
Plasma 14.1
Urine 11.6
0.625–40 ng/ml 4.2 14.9
31.3–2000 pg/ml 8.1 13.4
0.3–20 ng/ml 6.4 12.0
8.8 ng/ml 8.1 11.8
3.9–250 ng/ml 3.4 6.9
52.5–18716 pg/ml 4.6 12.3
10–9233 pg/ml 5.0 9.0
135–23246 pg/ml 5.8 17.7
123–23978 pg/ml 5.0 11.7
159–116,000 pg/ml 10.1 10.5
50–36,100 pg/ml 3.8 8.8
0.8 2.1
3
CLINICAL RESEARCH K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKDStatistical analysis was performed using GraphPad
(La Jolla, CA) Prism 7 XML and Stata 15.1 (StataCorp,
College Station, TX).RESULTS
Study Cohorts
The cases in the case-control group were 15 women with
CKD with superimposed preeclampsia. The controls were
(i) 45 women with CKD but without superimposed pre-
eclampsia matched for gestation and prepregnancy CKD
stage, (ii) 18 women without CKD but with preeclampsia
matched for gestation, and (iii) 20 womenwithout CKD or
preeclampsia matched for gestation. In addition, quanti-
ﬁcation of discriminatory biomarkers was carried out inTable 2. Nested case-control cohort demographics
Diagnosis Superimposed preeclampsia
n 15
Gestation of sample 33.0
Median (IQR) (30.6–34.7) (
Age (yr) 31.0
Median (IQR) (25.5–34.5) (
BMI (kg/m2) 26.0
Median (IQR) (23.8–32.8) (
Ethnicity
 White (%) 5 (33)
 Black (%) 7 (47)
 Asian (%) 0 (0)
 Other (%) 3 (20)
Nulliparous (%) 10 (67)
SBPa 119
Median (IQR) (110–122)
DBPa 74
Median (IQR) (70–83)
Chronic hypertension (%) 8 (53)
Treatment for BP <20 weeks/nonpregnant (%) 5 (33)
CKD stage
1 (%) 8 (53)
2 (%) 3 (20)
3 (%) 2 (13)
4 (%) 0 (0)
5 (%) 0 (0)
Unknown 2 (13)
Renal diagnosis (%)
Lupus 3 (20)
Non-lupus GN 2 (13)
Diabetic nephropathy 4 (27)
Reﬂux/CAKUT 2 (13)
Other 1 (7)
Unknown 3 (20)
Transplant (%) 2 (13)
$2þ Proteinuria at booking (%) 6 (40)
Nonpregnant PCRb >50 mg/mmol N/A
Prepregnancy DM (%) 4 (27)
BMI, body mass index; CAKUT, congenital abnormalities of kidney and urinary tract; CKD, chro
mellitus; GN, glomerulonephritis; N/A, no relevant data, i.e., gestation; PCR, protein:creatinine
aBlood pressure was the first value recorded in pregnancy or a nonpregnant value for nonpre
bData available for 14 women.
422 nonpregnant women with CKD stages 2 to 4 (median
estimated glomerular ﬁltration rate 35 ml/min per 1.73
m2, range 23–48ml/min per 1.73 m2). Standard diagnostic
criteria were used for the diagnosis or exclusion of
superimposed preeclampsia in 25% (15 of 60) of the
women with CKD. Demographic (Table 2) and outcome
data (Table 3) are shown.
The extended group used in the analysis of RAS
biomarkers was an extension of the case-control group
and included an additional 3 women with super-
imposed preeclampsia, 20 women with CKD but no
superimposed preeclampsia, 11 women with pre-
eclampsia, 23 women with chronic hypertension in the
absence of both CKD and preeclampsia, and 45 addi-
tional healthy pregnant controls. Demographic andCKD Preeclampsia Normal pregnancy Nonpregnant
45 18 20 22
32.0 33.3 33.1 N/A
30.3–33.7) (31.1–34.3) (27.6–33.7) N/A
34.0 31 31 35
28.9–36.1) (27.8–35.6) (29.0–33.3) (30.3–38.5)
24.0 27.0 23.2 N/A
22.3–29.8) (24.2–31.1) (21.1–28.5)
26 (58) 5 (28) 17 (85) 10 (45)
10 (22) 11 (61) 2 (10) 6 (27)
4 (16) 2 (11) 1 (5) 5 (23)
5 (11) 0 (0) 0 (0) 1 (5)
21 (47) 10 (56) 15 (75) N/A
115 120 109 126
(110–122) (111–128) (101–110) (120–136)
73 75 62 75
(66–80) (70–85) (60–70) (70–82)
16 (36) 5 (28) 0 (0) 14 (64)
10 (22) 2 (11) 0 (0) 13 (59)
32 (71) 0 (0) 0 (0) 0 (0)
6 (13) 0 (0) 0 (0) 1 (5)
7 (15) 0 (0) 0 (0) 14 (64)
0 (0) 0 (0) 0 (0) 5 (23)
0 (0) 0 (0) 0 (0) 2 (9)
0 (0) 0 (0) 0 (0) 0 (0)
15 (33) N/A N/A 2 (9)
10 (22) N/A N/A 9 (41)
2 (4) N/A N/A 1 (5)
4 (9) N/A N/A 5 (23)
4 (9) N/A N/A 1 (5)
10 (22) N/A N/A 4 (18)
3 (7) 0 (0) 0 (0) 9 (41)
15 (33) 0 (0) 0 (0) N/A
N/A N/A N/A 5 (36)
3 (7) 0 (0) 0 (0) 1 (5)
nic kidney disease (without preeclampsia); DBP, diastolic blood pressure; DM, diabetes
ratio; SBP, systolic blood pressure.
gnant controls
Kidney International Reports (2019) -, -–-
Table 3. Nested case-control pregnancy outcomes
Outcome
Superimposed preeclampsia (SPE)
(n [ 15a) CKD (n [ 45) Preeclampsia (n [ 18) Normal pregnancy (n [ 20b)
Clinical features of preeclampsia
Highest SBP 172i 130 170p 138
Median (IQR) (162–175) (120–146) (158–189) (130–140)
Highest DBP 97e 90 104p 83
Median (IQR) (91–106) (75–100) (97–108) (78–91)
Severe hypertension (SBP>160 or DBP>110 mm Hg) 11 (85)i 7 (16) 11 (61)p 0 (0)
Antihypertensives, i.v. (%) 3 (33)g 0 (0) 3 (17) 0 (0)
Magnesium sulphate, i.v. (%) 2 (13) 0 (0) 5 (28)j 0 (0)
Highest urine PCR 126 105 55 6c
Median (IQR) (113–662) (33–222) (45–82)
Doubling of proteinuria >30 mg/mmol (%) 10 (77)i 1 (2) 1 (6)q 0 (0)
ALT>70 IU/l (%) 0 (0) 3 (7) 3 (17) 0 (0)
Platelet count <100  109/l (%) 0 (0) 1 (2) 1 (6) 0 (0)
Delivery outcomes
Vaginal delivery (%) 1 (7)g 21 (47) 6 (33)m 16 (80)
Cesarean delivery (%) 14 (93)g 24 (53) 12 (67)m 4 (20)
Emergency cesarean delivery (%) 9 (60)d 14 (31) 8 (44) 3 (15)
Neonatal outcomes
Gestational age 34.0i 38.0 35.0k 40.6
Median (IQR) (32.4–36.6) (37.3–39.6) (32.6–35.4) (39.9–41.0)
Preterm <37 weeks (%) 11 (73)i 6 (13) 15 (83)p 0 (0)
Preterm <34 weeks (%) 5 (33)f 2 (4) 6 (33)l 0 (0)
NNU admission (%) 7 (47)h 2 (4) 9 (50)o 1 (5)
Birthweight, g 2050i 3132 1985p 3393
Median (IQR) (1284–2655) (2640–3220) (1588–2313) (3203–3715)
Birthweight <10th centile (%) 7 (47) 11 (24) 10 (55)n 2 (10)
Birthweight <3rd centile (%) 5 (33)f 2 (4) 6 (33)l 0 (0)
ALT, alanine aminotransferase; CKD, chronic kidney disease; DBP, diastolic blood pressure; NICU, neonatal intensive care unit; NNU, neonatal unit admission; PCR, protein:creatinine
ratio; SBP, systolic blood pressure.
aOutcome data for 11–15 women.
bOutcome data for 16–20 women.
cPCR quantified in a single healthy pregnant control.
Comparison between superimposed preeclampsia and CKD: dP ¼ 0.047, eP ¼ 0.026, fP ¼ 0.008, gP ¼ 0.004, hP ¼ 0.0004, iP < 0.0001.
Comparison between preeclampsia and normal pregnancy: jP ¼ 0.017, kP ¼ 0.014, lP ¼ 0.007, mP ¼ 0.005, nP ¼ 0.003, oP ¼ 0.002, pP < 0.0001.
Comparison between superimposed preeclampsia and preeclampsia: qP ¼ 0.0004.
K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKD CLINICAL RESEARCHoutcome data from this longitudinal group are shown
in Supplementary Table S1.
There were no signiﬁcant baseline differences in
women who developed superimposed preeclampsia
compared with those with CKD who did not develop
superimposed preeclampsia including age, body mass
index, black/nonblack ethnicity, parity, prevalence of
chronic hypertension, and booking levels of blood
pressure and proteinuria. Higher systolic and diastolic
blood pressures during pregnancy and a greater relative
increase in proteinuria in women with superimposed
preeclampsia were consistent with the criteria used for
diagnosis. Women with superimposed preeclampsia
delivered at an earlier gestation compared with women
with CKD who did not develop superimposed pre-
eclampsia. The infants of women with superimposed
preeclampsia were also more likely to be born both
preterm (<37 weeks) and very preterm (<34 weeks), be
small for gestational age, and require neonatal unit
admission. These differences were also evident in
women with preeclampsia in the absence of CKDKidney International Reports (2019) -, -–-compared with women with normal pregnancies. There
were no signiﬁcant differences in obstetric outcomes
between women with superimposed preeclampsia
compared with those with preeclampsia in the absence
of CKD, with the exception of proteinuria, which was
higher in women with superimposed preeclampsia
consistent with underlying CKD. The nonpregnant
controls were selected to allow biomarker quantiﬁcation
at higher stages of CKD; these women had an increased
prevalence of chronic hypertension and proportion of
women with renal transplants compared with pregnant
CKD groups. However, absolute levels of blood pressure
and rates of clinically signiﬁcant proteinuria were
comparable across all CKD study groups.
Discriminatory Biomarkers: Plasma Hyaluronan,
Plasma VCAM
Plasma hyaluronan and plasma VCAM concentrations
were signiﬁcantly higher in women with superimposed
preeclampsia compared with women with CKD in the
absence of superimposed preeclampsia, and in women5
Figure 1. Plasma hyaluronan (a) and plasma vascular cell adhesion molecule (VCAM) (b) concentrations in superimposed preeclampsia
(SPE), women with chronic kidney disease (CKD) who do not develop preeclampsia, women with preeclampsia (in the absence of CKD), normal
pregnancy (NP), and in nonpregnant controls with CKD stages 2–4 (bars at median and interquartile range).
CLINICAL RESEARCH K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKDwith preeclampsia compared with those with normal
pregnancies (Figure 1, Table 4). Area under the curve
estimations for prediction of superimposed pre-
eclampsia for hyaluronan were 0.98 (95% conﬁdence
interval [CI]: 0.94–1.00) for women without CKD and
0.80 (95% CI: 0.65–0.94) for women with CKD.
Equivalent values for VCAM were 0.91 (95% CI:
0.82–1.00) for women without CKD and 0.86 (95% CI:
0.71–1.00) for women with CKD (Figure 2, Table 4).
Sensitivity, speciﬁcity, positive and negative predic-
tive values are given in Table 5. Both plasma hyalur-
onan (P < 0.0001) and plasma VCAM (P < 0.0001)
showed a signiﬁcant correlation with PlGF, with an
increase in both biomarkers when PlGF was <10th
centile for gestation (Figure 3).
Plasma hyaluronan (P < 0.0001; geometric mean
ratio 4.93; 95% CI: 3.01–8.108) and plasma VCAM
concentrations (P < 0.0001; geometric mean ratio 1.88;
95% CI: 1.49–2.36) were also higher in preeclampsia (in
the absence of CKD) compared with CKD (in the
absence of preeclampsia) facilitating diagnostic
distinction between previously unknown or new CKD
in pregnancy, from preeclampsia.
There was no detectable difference in hyaluronan
concentration in nonpregnant women with CKD stage
2–4 (median 32.2 ng/ml, interquartile range [IQR] 20.3–
44.0 ng/ml) compared with both normal pregnancy
(geometric mean ratio 0.79; 95% CI: 0.50–1.26; P ¼
0.23) and CKD in the absence of preeclampsia (geo-
metric mean ratio 0.98; 95% CI: 0.66–1.46; P ¼ 0.52).
However, plasma VCAM was increased in nonpregnant
women with CKD stage 2–4 (median 857 ng/ml; IQR
711–1270 ng/ml) compared with both normal preg-
nancy (geometric mean ratio 1.54; 95% CI: 1.22–1.94;
P ¼ 0.005) and CKD in the absence of superimposed
preeclampsia (geometric mean ratio 1.38; 95% CI: 1.12–
1.70; P ¼ 0.03), although this was not explained by the
higher number of women with renal transplants in the6nonpregnant group. No detectable difference in VCAM
concentration was detected in nonpregnant women
with renal transplants (median 857 ng/ml; IQR 670–
1151 ng/ml) compared with those without (median 883
ng/ml; IQR 698–1442 ng/ml), and differences in plasma
VCAM concentration in superimposed preeclampsia
(median 1476 ng/ml; IQR 911–2136 ng/ml) compared
with CKD (median 688 ng/ml; IQR 559–858 ng/ml)
remained after exclusion of women with renal trans-
plants (P < 0.0001).
Prepregnancy estimated glomerular ﬁltration
rate and gestation were not signiﬁcant modiﬁers
of either hyaluronan or VCAM concentration (see
Supplementary Table S2).
Variable Discrimination: Plasma Active Renin,
Urinary Angiotensinogen:Creatinine
Plasma active renin was lower in superimposed pre-
eclampsia compared with CKD (geometric mean ratio
0.27; 95% CI: 0.15–0.49) and in preeclampsia compared
with normal pregnancy (geometric mean ratio 0.18;
95% CI: 0.13–0.27) (Table 4). However, active renin
concentrations were also lower in women with chronic
hypertension compared with normotensive pregnant
women (median 8.2 pg/ml; IQR 3.5–15.7) versus 17.2
pg/ml (IQR 12.2–25.0; P < 0.0001; geometric mean ratio
0.40; 95% CI: 0.30–0.53) and the detected correlation
between active renin and PlGF in normotensive women
(r ¼ 0.33; 95% CI: 0.17–0.48; P < 0.0001) was not
evident in women with chronic hypertension (r ¼ 0.06;
95% CI: 0.14 to 0.26; P ¼ 0.55). Urinary angio-
tensinogen:creatinine was higher in superimposed
preeclampsia compared with CKD (geometric mean ra-
tio 8.72; 95% CI: 3.07–24.76), and in preeclampsia
compared with normal pregnancy (geometric mean ratio
3.65; 95% CI: 1.32–10.07) (Table 4), although there was
no measurable correlation between urinary angiotensi-
nogen:creatinine and PlGF centile (r ¼ 0.14; 95%Kidney International Reports (2019) -, -–-
Table 4. Quantiﬁcation of biomarkers in superimposed preeclampsia, CKD (without preeclampsia), preeclampsia (without CKD), and in normal pregnancy
Biomarker
Plasma/
urine
Superimposed
preeclampsia CKD Pa
Geometric mean
ratioa (95% CI)
ROC AUCa
(95% CI) Preeclampsia
Normal
pregnancy Pb
Geometric mean
ratiob (95% CI)
ROC AUCb
(95% CI)
Discriminatory
Hyaluronan (ng/ml) Plasma 67.5 (39.5–160) 27.5 (15.4–42.5) 0.0017 2.47 (1.49–4.07) 0.80 (0.65–0.94) 123.7 (82.9–160) 32.2 (20.3–44.0) <0.0001 6.12 (3.53–10.62) 0.98 (0.94–1.00)
VCAM (ng/ml) Plasma 1132 (1060–1979) 659 (556–857) <0.0001 1.89 (1.46–2.44) 0.86 (0.71–1.00) 1275 (966–1748) 579 (442–840) <0.0001 2.09 (1.62–2.69) 0.91 (0.82–1.00)
PlGF centilec Plasma 0 (0–4) 18 (8–40) 0.002 0 (0–1)
Variable discrimination
Active renin (pg/ml) Plasma 2.87 (1.12–6.15) 11.18 (6.48–19.01) 0.02 0.27 (0.15–0.49) 0.89 (0.77–1.00) 5.56 (0.81–9.58) 17.19 (12.22–24.94) <0.0001 0.18 (0.13–0.27) 0.92 (0.86–0.98)
Angiotensinogen:creatinine
(ng/micromol)
Urine 127.5 (61.0–166.6) 9.7 (3.8–27.6) <0.001 8.72 (3.07–24.76) 0.89 (0.78–1.00) 18.6 (6.8–85.9) 7.1 (2.7–15.6) <0.01 3.65 (1.32–10.07) 0.76 (0.63–0.89)
CFH (mcg/ml) Plasma 1053 (616–1228) 1060 (886–1194) 0.69 0.87 (0.72–1.06) 0.54 (0.31–0.77) 672 (567–805) 1116 (1006–1171) <0.0001 0.62 (0.50–0.78) 0.91 (0.80–1.00)
Nondiscriminatory
Angiotensinogen (ng/ml) Plasma 121 (87–137) 111 (86–131) 0.53 1.22 (0.60–2.48) 0.57 (0.33–0.81) 107 (70–131) 114 (89–150) 0.07 0.59 (0.40–0.87) 0.39 (0.28–0.50)
C3a (ng/ml) Plasma 63.5 (48.0–74.5) 49.8 (41.1–64.3) 0.15 1.16 (0.91–1.49) 0.64 (0.46–0.83) 43.7 (29.6–60.2) 34.2 (30.2–50.3) 0.48 1.13 (0.85–1.50) 0.59 (0.35–0.82)
C3a:creatinine
(ng/micromol)
Urine 45.2 (10.2–236.3) 46.7 (11.4–233) 0.78 0.84 (0.26–2.77) 0.47 (0.24–0.69) 14.2 (11.4–30.5) 4.2 (4.2–24.2) 0.53 2.45 (0.33–18.23) 0.64 (0.22–1.00)
C5a (ng/ml) Plasma 1.25 (1.25–1.28) 1.25 (1.25–1.65) 0.49 0.45 (0.07–2.81) 0.44 (0.289–0.59) 1.25 (1.25–2.17) 1.45 (1.25–3.37) 0.19 0.27 (0.05–1.61) 0.37 (0.19–0.55)
C5b-9 (ng/ml) Plasma 367 (297–509) 339 (249–443) 0.29 1.24 (0.93–1.65) 0.61 (0.43–0.79) 294 (225–429) 238 (193–360) 0.30 1.13 (0.84–1.51) 0.61 (0.40–0.82)
C5b-9:creatinine
(ng/micromol)
Urine 3.02 (0.30–4.80) 0.60 (0.33–1.69) 0.25 2.04 (0.74–5.67) 0.62 (0.40–0.84) 0.73 (0.43–0.98) 0.41 (0.41–0.73) 0.31 1.08 (0.34–3.42) 0.62 (0.35–0.89)
E-selectin (ng/ml) Plasma 34.1 (21.0–49.4) 39.6 (27.7–43.7) 0.80 1.01 (0.76–1.35) 0.53 (0.31–0.75) 46.7 (24.2–55.8) 35.2 (26.6–43.2) 0.15 1.24 (0.93–1.64) 0.64 (0.44–0.84)
ICAM (ng/ml) Plasma 121.5 (87.7–152.1) 147.0 (115.5–171.4) 0.13 0.67 (0.47–0.97) 0.35 (0.14–0.56) 137.7 (102.9–182.2) 131.2 (105.1–154.5) 0.64 1.11 (0.78–1.60) 0.55 (0.34–0.75)
KIM-1 (pg/ml) Plasma 352 (313–402) 313 (273–402) 0.42 1.07 (0.85–1.35) 0.66 (0.40–0.91) 293 (253–303) 263 (253–290) 0.47 1.05 (0.81–1.35) 0.43 (0.00–0.88)
Lipocalin-2:creatinine
(ng/micromol)
Urine 10.3 (3.8–25.6) 11.1 (5.8–32.9) 0.60 1.53 (1.09–2.14) 0.44 (0.23–0.65) 7.9 (4.8–12.8) 1.7 (1.0–6.2) 0.05 0.76 (0.52–1.10) 0.73 (0.51–0.95)
P-selectin (ng/ml) Plasma 55.2 (39.3–66.4) 52.4 (40.4–62.6) 0.82 1.04 (0.84–1.28) 0.52 (0.33–0.72) 53.3 (41.0–68.8) 57.7 (44.7–71.1) 0.37 0.87 (0.71–1.07) 0.41 (0.22–0.60)
CFH, complement factor H; CI, conﬁdence interval; CKD, chronic kidney disease; ICAM, intracellular adhesion molecule; KIM-1, Kidney Injury Molecule-1; PlGF, placenta growth factor; ROC AUC, area under the receiver operating curve; VCAM,
vascular cell adhesion molecule.
aComparison between CKD and superimposed preeclampsia.
bComparison between preeclampsia and normal pregnancy.
cPlGF centile not derived >37 weeks’ gestation.
Values are median (interquartile range).
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Figure 2. Receiver operating characteristic (ROC) curve of plasma hyaluronan (a) and plasma vascular cell adhesion molecule (VCAM) (b) in
the diagnosis of preeclampsia in women with (red) and without (black) chronic kidney disease (CKD). Values are area under the curve with
95% conﬁdence intervals.
CLINICAL RESEARCH K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKDCI: 0.28 to 0.11; P ¼ 0.06). The diagnostic discrimi-
nation of both plasma active renin and urinary angio-
tensinogen:creatinine was reduced in women with
chronic hypertension, women requiring antihyperten-
sive treatment before 20 weeks’ gestation and in black
ethnicity (Table 6).
Plasma complement factor H was lower in pre-
eclampsia compared with normal pregnancy. However,
no detectable differences were seen in superimposed
preeclampsia where diagnostic distinction was poor
(Table 4).
Nondiscriminatory Markers
Quantiﬁcation of plasma angiotensinogen, C3a, C5a,
C5b-9, E-selectin, intercellular adhesion molecule,
Kidney Injury Molecule-1, and P-selectin, and urinary
lipocalin-2 failed to discriminate women with super-
imposed preeclampsia from CKD in the absence of
preeclampsia, and preeclampsia from normal
pregnancy.
DISCUSSION
Diagnosis of superimposed preeclampsia remains chal-
lenging in women with CKD, and underlying patho-
physiology predisposing to increased risk is poorly
understood. This study demonstrates that quantiﬁca-
tion of plasma hyaluronan and plasma VCAM have the
potential to distinguish superimposed preeclampsia in
pregnant women with CKD. Correlation of bothTable 5. Sensitivity, speciﬁcity, positive and negative predictive values (%
women with and without CKD
Biomarker
Sensitivity Speciﬁcity
CKD No CKD CKD No
Hyaluronan >39 ng/ml 82 (47–97) 93 (66–97) 74 (58–86) 82 (5
VCAM >950 ng/ml 82 (48–97) 80 (51–95) 91 (77–97) 91 (7
CKD, chronic kidney disease; VCAM, vascular cell adhesion molecule.
8hyaluronan and VCAM with serum PlGF concentration
supports the diagnostic criteria used in this study to
deﬁne superimposed preeclampsia. Suggested cutoffs of
for the diagnosis of preeclampsia of >39 ng/ml for
plasma hyaluronan and >950 ng/ml for plasma VCAM
have a sensitivity of 82% and a negative predictive
value of 94% to 95% in women with CKD. All other
markers tested showed variable discrimination or failed
to discriminate preeclampsia in women with and
without CKD.
Plasma hyaluronan and VCAM are components of
the endothelial cell glycocalyx, which is a negatively
charged protective layer that sits between the endo-
thelial cell surface and the ﬂow of blood. It is thought
to play a physiological role in vascular protection,
modulation, and hemostasis.36 An increase in circu-
lating concentrations of hyaluronan and VCAM is hy-
pothesized to represent damage to the endothelial
glycocalyx. The model of preeclampsia as an endothe-
lial disorder driven by placentally derived anti-
angiogenic factors is supported by both the systemic
nature of disease and its resolution following de-
livery.14 Endothelial dysfunction in CKD is manifest by
accelerated vascular disease, as well as proteinuria,
which is a clinical manifestation of intrarenal endo-
thelial disease.15 Thus, endothelial glycocalyx
dysfunction provides a mechanistic link between CKD
and preeclampsia, whereby damage to the endothelial
glycocalyx in CKD confers vulnerability to additional) with 95% conﬁdence intervals for the prediction of preeclampsia in
Negative predictive
value
Positive predictive
value
CKD CKD No CKD CKD No CKD
6–95) 94 (77–99) 93 (66–100) 47 (25–71) 84 (56–95)
0–98) 95 (82–99) 88 (66–97) 69 (39–90) 86 (56–97)
Kidney International Reports (2019) -, -–-
Figure 3. Correlation of plasma hyaluronan and plasma vascular
cell adhesion molecule (VCAM) with placenta growth factor (PlGF)
centile measured by Spearman’s rank correlation coefﬁcient.
K Wiles et al.: Biomarkers of Superimposed Preeclampsia in CKD CLINICAL RESEARCHinjury in preeclampsia, offering a potential explanation
for the increased rates of superimposed preeclampsia
seen in women with CKD.3,5 Although increases in both
plasma hyaluronan and VCAM have been similarly
shown in small cohort studies of pregnant women
without underlying CKD,37–41 including women with
chronic hypertension,42 this is the ﬁrst report showing
utility in pregnant women with CKD. This study also
demonstrates the potential capacity of these markers to
distinguish preeclampsia from a new diagnosis of CKD
in pregnancy; a phenomenon that represents up to one-
third of CKD in pregnancy.43 Receiver operating curve
areas of 0.80–0.86 are higher than those for clinical
variables including systolic and diastolic blood pres-
sure and the detection of de novo proteinuria on urine
dipstick testing, which may not distinguish the need
for delivery due to preeclampsia even in the absence of
complicating CKD.9
Biomarkers of the RAS evaluated in this study
included plasma active renin, plasma angiotensinogen,
and urinary angiotensinogen:creatinine. Concentra-
tions of plasma active renin were signiﬁcantly lower in
both preeclampsia and superimposed preeclampsia
consistent with previously published data,44 and theTable 6. Area under the receiver operating curve values (SE) for the dia
angiotensinogen:creatinine in women with and without underlying CKD, ad
and black/nonblack ethnicity
Plasma active renin
CKD
All extended cohort 0.80 (0.12)
Women without CHT 0.92 (0.04)
Women with CHT 0.61 (0.38)
No antihypertensive use <20 wk 0.92 (0.04)
Antihypertensive use <20 wk 0.61 (0.39)
Nonblack ethnicity 0.90 (0.05)
Black ethnicity 0.71 (0.26)
CHT, chronic hypertension; CKD, chronic kidney disease.
Kidney International Reports (2019) -, -–-consensus hypothesis that hypertension in preeclamp-
sia is due to an exaggerated pressor response to RAS,
rather than a measurable increase in RAS compo-
nents.45,46 The ﬁnding of an increase in urinary
angiotensinogen in preeclampsia without a measured
increase in plasma levels raises the possibility of
intrarenal synthesis of angiotensinogen in preeclamp-
sia, with excretion into urine where it can be measured.
This is substantiated by reports of angiotensinogen
gene expression in renal biopsy tissue,47 and the use of
urinary angiotensinogen:creatinine as a marker of
intrarenal RAS activation in both hypertension48,49 and
CKD.47,50,51 However, diagnostic discrimination of both
plasma active renin and urinary angiotensinogen:crea-
tinine was reduced in the context of known modiﬁers
of RAS, including chronic hypertension,26–28 hyper-
tensive drug use,52 and ethnicity.28 Such modiﬁers are
important, as their prevalence in CKD cohorts is high.
In this study, 40% (24/60) of women with CKD were
hypertensive before pregnancy, which is comparable to
other published cohorts,3,4 25% (15/60) were using
antihypertensive medication before 20 weeks’ gesta-
tion, and 28% (17/60) of women were of black
ethnicity. In addition, gestational changes in angio-
tensinogen are described, including an altered ratio of
oxidized to reduced forms in preeclampsia,53 poly-
morphic conformational change, and pregnancy-
speciﬁc high molecular weight forms.54,55 Such
factors may contribute to the inconsistency in pub-
lished data with reports both supporting56 and
refuting57 an association between high urinary angio-
tensinogen:creatinine and complicated pregnancy
including preeclampsia. In the context of multiple
confounders, the use of RAS biomarkers in the diag-
nosis of superimposed preeclampsia is likely to be
complex, with limited clinical utility.
This multicenter study is novel in examining a well-
deﬁned cohort of pregnant women with CKD, rather
than a mixed cohort of high-risk women; and in spe-
ciﬁcally examining for differences between women
with CKD who do, and do not develop superimposedgnosis of preeclampsia using plasma active renin and urinary
justed for CHT, antihypertensive drug use before 20 weeks’ gestation,
Urinary angiotensinogen:creatinine
No CKD CKD No CKD
0.88 (0.03) 0.82 (0.08) 0.80 (0.04)
0.92 (0.04) 0.90 (0.06) 0.86 (0.04)
0.76 (0.09) 0.68 (0.26) 0.61 (0.14)
0.92 (0.03) 0.88 (0.07) 0.83 (0.05)
0.73 (0.14) 0.67 (0.27) 0.65 (0.17)
0.92 (0.04) 0.89 (0.08) 0.85 (0.05)
0.76 (0.08) 0.69 (0.17) 0.64 (0.12)
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explore mechanistic pathways. The diagnostic criteria
for preeclampsia superimposed on CKD are ambig-
uous2,58; however, this study used predeﬁned blood
pressure and proteinuria thresholds and expert diag-
nostic consensus masked to biomarker concentrations
for all complex cases. In addition, correlation with PlGF
was used as a conﬁrmatory diagnostic adjunct. This
was done on the basis of supporting data in women
with a combination of chronic hypertension and/or
CKD that demonstrate a capacity to predict the need for
delivery, a low false-positive rate (3/161), and inde-
pendence from serum creatinine.4 Although circulating
s-Flt1 levels were not assessed in this study, no dif-
ference has been demonstrated between the diagnostic
performance of PlGF centile when compared with s-Flt1
concentration or s-Flt-1:PlGF ratio in women with CKD
and chronic hypertension.4,59
This study is limited by the sample size. Despite
matching for prepregnancy CKD stage, the possibility
that reduced renal clearance impacts biomarker quan-
tiﬁcation also warrants further assessment. Although
concentrations of hyaluronan in nonpregnant women
with CKD stages 2 to 4 were comparable to that in
normal pregnancy, concentrations of VCAM were
increased in both superimposed preeclampsia and
nonpregnant CKD. Although increased calcineurin in-
hibitors have been associated with increased VCAM
messenger RNA synthesis,60 exclusion of women with
renal transplants from the study data had no impact on
the results, suggesting the possibility of confounding
by reduced glomerular ﬁltration. There are limited data
showing increases in both hyaluronan61 and VCAM15
with reduced renal function and validation of the
diagnostic capacity of these markers in pregnant
women with advanced CKD is warranted. The urinary
markers in this study used a ratio to urinary creatinine
to correct for urinary ﬂow rate and concentration. This
was based on an assumption that urinary creatinine
excretion is constant, and that biomarker excretion has
a linear relationship with creatinine excretion,62 which
does not explicitly address ethnic differences in
creatinine production and excretion, or false ampliﬁ-
cation due to acute kidney injury, which may exist in
the context of both preeclampsia and superimposed
preeclampsia. Recruitment to this study was pragmatic,
with samples taken from participants at their conve-
nience, coordinated with other hospital attendances. In
the absence of a standardized gestation over which
longitudinal changes in biomarker concentration could
be examined, analysis was restricted to concentrations
at the time of disease (preeclampsia/superimposed
preeclampsia) when biomarker changes were10anticipated to be most exaggerated. Whether longitu-
dinal changes in biomarker concentration are predic-
tive or diagnostic of superimposed preeclampsia
remains unknown.
The ﬁndings of this exploratory study suggest that
quantiﬁcation of plasma hyaluronan and VCAM have
the potential to aid in the diagnosis of superimposed
preeclampsia. Current standard diagnostic criteria can
be used only in women who do not have preexisting
hypertension and proteinuria, excluding 75% of
women with CKD in this cohort. Test performances for
plasma hyaluronan and VCAM are comparable to that
of soluble fms-like tyrosine kinase-1:PlGF ratio >85,4
which is based on an antiangiogenic, placental driven
model of preeclampsia. However, a placental model of
disease may be an inadequate representation of the
pathophysiology of superimposed preeclampsia in
women with CKD. The consistent association between
CKD and preeclampsia, including an increment in the
risk of preeclampsia with increasing CKD severity,
suggests a signiﬁcant maternal contribution to the
disease process in superimposed preeclampsia. Yet,
mechanisms by which maternal CKD inﬂuences the
pathology of preeclampsia remain unknown, and
maternal drivers of disease are unmeasured with the
isolated use of placental biomarkers. Quantiﬁcation of
plasma hyaluronan and VCAM therefore offers a po-
tential measure of “maternal disease” in the prediction,
diagnosis, and long-term prognosis of superimposed
preeclampsia in women with CKD. The ﬁndings of this
study warrant validation in a larger, prospective cohort
including pregnant women with advanced stage CKD,
and multivariable analysis to assess the diagnostic
value of these novel biomarkers over existing clinical
parameters including PlGF and soluble fms-like tyro-
sine kinase-1.
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